Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany;
Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, Münster, Germany.
Anticancer Res. 2023 Nov;43(11):4975-4981. doi: 10.21873/anticanres.16696.
BACKGROUND/AIM: Ewing sarcoma can arise in patients after osteosarcoma or vice versa. Our aim was to learn more about which patients develop these secondary tumors, which treatments may be effective, and which patients might survive.
The database of the Cooperative Osteosarcoma Study Group (1980-09/2022) was searched for all patients with an osteosarcoma (including undifferentiated pleomorphic sarcoma of the bone) who also suffered from Ewing sarcoma (incl. peripheral neuroectodermal tumor) at any time, previously or thereafter. The identified patients were then analyzed for patient, tumor, and treatment-related variables as well as their disease- and survival-status at the last follow-up.
A total of 20 eligible patients [17 Ewing sarcoma prior to osteosarcoma, 3 vice versa; 10 males, 10 females; median age at 1 cancer 10.5 (2.4-20.6), at 2 cancer 20.5 (9.9-42.4) years] were identified. None of the patients developed a 3rd cancer and none had a known tumor-predisposition syndrome. Sixteen/17 secondary osteosarcomas and no secondary Ewing sarcoma developed in sites that had previously been irradiated. Nineteen/20 (95%) patients received primary multi-agent chemotherapy for their 1 and 2 cancers. Actuarial overall and event-free survival probabilities at five years after the diagnosis of the secondary cancer were 69% and 42%, respectively.
Secondary osteosarcoma arising after Ewing sarcoma is almost exclusively associated with radiation. This is not the case vice versa. Either way, long-term survival is a realistic possibility with appropriate multidisciplinary treatment; thus, therapeutic negligence is clearly inadequate.
背景/目的:尤文肉瘤可继发于骨肉瘤,反之亦然。我们的目的是更多地了解哪些患者会发生这些继发性肿瘤,哪些治疗可能有效,以及哪些患者可能存活。
合作骨肉瘤研究组的数据库(1980-09/2022)被搜索,以寻找所有曾经或之后在任何时间患有骨肉瘤(包括骨未分化多形性肉瘤)的同时患有尤文肉瘤(包括外周神经外胚层肿瘤)的患者。然后,对这些患者进行分析,以了解患者、肿瘤和治疗相关的变量,以及他们在最后一次随访时的疾病和生存状况。
共确定了 20 名符合条件的患者[17 名尤文肉瘤继发于骨肉瘤,3 名骨肉瘤继发于尤文肉瘤;10 名男性,10 名女性;1 种癌症时的中位年龄为 10.5(2.4-20.6)岁,2 种癌症时为 20.5(9.9-42.4)岁]。没有患者发生第 3 种癌症,也没有已知的肿瘤易感性综合征。16/17 例继发性骨肉瘤和无继发性尤文肉瘤发生在先前接受过放疗的部位。19/20(95%)名患者接受了原发性多模式化疗治疗其 1 种和 2 种癌症。继发性癌症诊断后 5 年的总生存率和无事件生存率分别为 69%和 42%。
继发于尤文肉瘤的继发性骨肉瘤几乎总是与放疗有关。反之则不然。无论哪种情况,适当的多学科治疗都有可能实现长期生存;因此,治疗上的疏忽显然是不够的。